Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECIGEN, INC.XON · Entity 4356 | Chief Science Officer | January 04, 2020 | January 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECIGEN, INC.
Report date January 04, 2020 · Filed January 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 148,888 |
Ending reported balance
After 2020-01-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-01-04 · Exercise / conversion · Acquired 18,940 · Balance 154,304 F1: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Row 2 · 2020-01-06 · Sale · Disposed 5,416 · Balance 148,888 F2: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 56,818 |
Reported balance
After 2020-01-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-04 · Exercise / conversion · Disposed 18,940 · Balance 56,818 F1: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F5: The restricted stock units were granted on January 4, 2019, and the remaining restricted stock units vest in three equal annual installments on each of January 4, 2021, 2022 and 2023. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 62,840 |
Reported balance
Holding disclosure · report date 2020-01-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 62,840 F3: Held by the Thomas David Reed Living Trust dated February 4, 2011. |
| Common StockSEC Table I · non-derivative | IndirectBy trust of spouse | 41,705 |
Reported balance
Holding disclosure · report date 2020-01-04 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 41,705 F4: Held by the Jacquelyn Ann Reed Living Trust dated February 4, 2011. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 2,440 |
Reported balance
Holding disclosure · report date 2020-01-04 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,440 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of XON common stock.
F2: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units.
F3: Held by the Thomas David Reed Living Trust dated February 4, 2011.
F4: Held by the Jacquelyn Ann Reed Living Trust dated February 4, 2011.
F5: The restricted stock units were granted on January 4, 2019, and the remaining restricted stock units vest in three equal annual installments on each of January 4, 2021, 2022 and 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2020 Filed Jan 7, 2020 22:14 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 5,416 | $5.83 | $31,571.49 |
DisclosureSEC source: 0001123292-20-000111 · edgar.xml · nonDerivative · entry 2 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,888 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| January 04, 2020 Filed Jan 7, 2020 22:14 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 18,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000111 · edgar.xml · derivative · entry 6 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,818 Underlying: Common Stock · 18,940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F5 · derivative.exercise_date: The restricted stock units were granted on January 4, 2019, and the remaining restricted stock units vest in three equal annual installments on each of January 4, 2021, 2022 and 2023. F5 · derivative.expiration_date: The restricted stock units were granted on January 4, 2019, and the remaining restricted stock units vest in three equal annual installments on each of January 4, 2021, 2022 and 2023. Read SEC document |
| January 04, 2020 Filed Jan 7, 2020 22:14 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 18,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-20-000111 · edgar.xml · nonDerivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:15 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 2,986 | $5.77 | $17,228.92 |
DisclosureSEC source: 0001123292-20-000068 · edgar.xml · nonDerivative · entry 2 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,364 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:32 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 3,533 | $5.60 | $19,784.80 |
DisclosureSEC source: 0001123292-20-000041 · edgar.xml · nonDerivative · entry 2 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,584 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:15 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 9,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000068 · edgar.xml · derivative · entry 6 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,531 Underlying: Common Stock · 9,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F5 · derivative.exercise_date: The restricted stock units were granted on January 2, 2018, and the remaining restricted stock units vest in two equal annual installments on each of January 2, 2021 and 2022. F5 · derivative.expiration_date: The restricted stock units were granted on January 2, 2018, and the remaining restricted stock units vest in two equal annual installments on each of January 2, 2021 and 2022. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:15 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 9,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-20-000068 · edgar.xml · nonDerivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:32 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 14,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-20-000041 · edgar.xml · derivative · entry 6 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,340 Underlying: Common Stock · 14,340 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F5 · derivative.exercise_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest on March 31, 2020. F5 · derivative.expiration_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest on March 31, 2020. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:32 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 14,340 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-20-000041 · edgar.xml · nonDerivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 21:25 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 3,658 | $5.50 | $20,104.00 |
DisclosureSEC source: 0001123292-19-001191 · edgar.xml · nonDerivative · entry 2 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,777 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:25 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 14,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-001191 · edgar.xml · derivative · entry 6 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,680 Underlying: Common Stock · 14,341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F5 · derivative.exercise_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest in two equal quarterly installments on each of December 31, 2019 and March 31, 2020. F5 · derivative.expiration_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest in two equal quarterly installments on each of December 31, 2019 and March 31, 2020. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:25 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 14,341 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-001191 · edgar.xml · nonDerivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 23:12 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 3,527 | $7.76 | $27,369.52 |
DisclosureSEC source: 0001123292-19-000963 · edgar.xml · nonDerivative · entry 2 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,094 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 23:12 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 14,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-000963 · edgar.xml · derivative · entry 6 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,021 Underlying: Common Stock · 14,341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F5 · derivative.exercise_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest in three equal quarterly installments on each of September 30, 2019, December 31, 2019 and March 31, 2020. F5 · derivative.expiration_date: The restricted stock units were granted on April 9, 2019, and the remaining restricted stock units vest in three equal quarterly installments on each of September 30, 2019, December 31, 2019 and March 31, 2020. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 23:12 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 14,341 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000963 · edgar.xml · nonDerivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| April 09, 2019 Filed Apr 12, 2019 01:42 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantRestricted Stock Units · Derivative | 57,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-000630 · edgar.xml · derivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,362 Underlying: Common Stock · 57,362 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal quarterly installments beginning June 30, 2019. F2 · derivative.expiration_date: The restricted stock units vest in four equal quarterly installments beginning June 30, 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 02:07 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 2,300 | $4.66 | $10,718.00 |
DisclosureSEC source: 0001123292-19-000444 · edgar.xml · nonDerivative · entry 4 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By trust of spouse Disclosed balance after: 41,705 F1 · kind: Sale undertaken by reporting person's lender to whom the shares were pledged. F3 · ownership.nature: Held by the Jacquelyn Ann Reed Living Trust dated February 4, 2011. Read SEC document |
| March 04, 2019 Filed Mar 7, 2019 02:07 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 44,000 | $4.22 | $185,680.00 |
DisclosureSEC source: 0001123292-19-000444 · edgar.xml · nonDerivative · entry 3 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By trust of spouse Disclosed balance after: 44,005 F1 · kind: Sale undertaken by reporting person's lender to whom the shares were pledged. F3 · ownership.nature: Held by the Jacquelyn Ann Reed Living Trust dated February 4, 2011. Read SEC document |
| March 04, 2019 Filed Mar 7, 2019 02:07 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 165,000 | $4.17 | $688,050.00 |
DisclosureSEC source: 0001123292-19-000444 · edgar.xml · nonDerivative · entry 2 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By trust of spouse Disclosed balance after: 88,005 F1 · kind: Sale undertaken by reporting person's lender to whom the shares were pledged. F3 · ownership.nature: Held by the Jacquelyn Ann Reed Living Trust dated February 4, 2011. Read SEC document |
| March 04, 2019 Filed Mar 7, 2019 02:07 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 16,500 | $4.24 | $69,960.00 |
DisclosureSEC source: 0001123292-19-000444 · edgar.xml · nonDerivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 62,840 F1 · kind: Sale undertaken by reporting person's lender to whom the shares were pledged. F2 · ownership.nature: Held by the Thomas David Reed Living Trust dated February 4, 2011. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 21:57 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionOption to Purchase Common Stock (Right to Buy) · Derivative | 2,969 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001123292-19-000231 · edgar.xml · derivative · entry 2 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,969 shares Expires 2019-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was immediately exercisable. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 21:57 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 2,969 | $3.17 | $9,411.73 |
DisclosureSEC source: 0001123292-19-000231 · edgar.xml · nonDerivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 01:06 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantRestricted Stock Units · Derivative | 75,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-000128 · edgar.xml · derivative · entry 2 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,758 Underlying: Common Stock · 75,758 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 4, 2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 4, 2020. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 01:06 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantCommon Stock | 13,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000128 · edgar.xml · nonDerivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,311 F1 · price: These shares of common stock resulted from the grant and immediate vesting of restricted stock units that were issued as a portion of the reporting person's 2018 incentive compensation. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 23:47 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 2,944 | $7.07 | $20,815.55 |
DisclosureSEC source: 0001123292-19-000085 · edgar.xml · nonDerivative · entry 2 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,537 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:47 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 9,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-000085 · edgar.xml · derivative · entry 3 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,297 Underlying: Common Stock · 9,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 2, 2018, and the remaining restricted stock units vest in three equal annual installments on each of January 2, 2020, 2021 and 2022. F3 · derivative.expiration_date: The restricted stock units were granted on January 2, 2018, and the remaining restricted stock units vest in three equal annual installments on each of January 2, 2020, 2021 and 2022. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:47 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 9,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000085 · edgar.xml · nonDerivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:56 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 30,000 | $6.36 | $190,671.00 |
DisclosureSEC source: 0001123292-19-000030 · edgar.xml · nonDerivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,715 F1 · kind: Sale undertaken by reporting person's lender to whom the shares were pledged. Read SEC document |
| January 02, 2018 Filed Jan 9, 2018 01:21 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantRestricted Stock Units · Derivative | 39,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-18-000104 · edgar.xml · derivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,063 Underlying: Common Stock · 39,063 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 2, 2019. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 2, 2019. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 20:59 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionOption to Purchase Common Stock (Right to Buy) · Derivative | 8,906 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001225385-17-000108 · edgar.xml · derivative · entry 4 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,906 shares Expires 2018-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was immediately exercisable. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 20:59 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionOption to Purchase Common Stock (Right to Buy) · Derivative | 29,692 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001225385-17-000108 · edgar.xml · derivative · entry 3 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,692 shares Expires 2017-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was immediately exercisable. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 20:59 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 8,906 | $2.64 | $23,511.84 |
DisclosureSEC source: 0001225385-17-000108 · edgar.xml · nonDerivative · entry 2 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 20:59 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 29,692 | $2.64 | $78,386.88 |
DisclosureSEC source: 0001225385-17-000108 · edgar.xml · nonDerivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 22:16 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantOption to Purchase Common Stock (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $20.94 | $0.00 |
DisclosureSEC source: 0001225385-17-000010 · edgar.xml · derivative · entry 1 Reed Thomas D. · CIK 0001583188 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: The option vests in four 25% installments beginning on February 2, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.